CTC Awarded as CRO
It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC), has been awarded as clinical contract resource organisation (CRO) to execute our upcoming phase I study with our lead candidate PN6047. The study is planned to start in the second quarter of 2022 aiming to investigate safety and tolerability in healthy volunteers. This is a study combining a single ascending dose (SAD) part together with a multiple ascending dose (MAD) part under one common protocol. Following a thorough process in which several European CRO:s submitted their proposals for our evaluation, CTC was awarded based on value for money and an excellent audit. CTC is located in Uppsala, Sweden, and has long experience in conducting early phase studies and fulfilled all our expectations as set-out in our Request for Proposals documentation. We look forward to the collaboration with excitement.
CTC Awarded as CRO
It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC), has been awarded as clinical contract resource organisation (CRO) to execute our upcoming phase I study with our lead candidate PN6047. The study is planned to start in the second quarter of 2022 aiming to investigate safety and tolerability in healthy volunteers. This is a study combining a single ascending dose (SAD) part together with a multiple ascending dose (MAD) part under one common protocol. Following a thorough process in which several European CRO:s submitted their proposals for our evaluation, CTC was awarded based on value for money and an excellent audit. CTC is located in Uppsala, Sweden, and has long experience in conducting early phase studies and fulfilled all our expectations as set-out in our Request for Proposals documentation. We look forward to the collaboration with excitement.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
